Elan Outlines Options For Tysabri If Biogen Idec Is Sold
This article was originally published in The Pink Sheet Daily
Executive Summary
Larger pharmas, including Pfizer and Johnson & Johnson, are likely among the potential acquirers.
You may also be interested in...
Biogen Hires Outside Help To Evaluate Acquisition Interest
Activist investor Carl Icahn is among those interested in the biotech.
Joint Panel Recommends Tysabri For Crohn’s Disease
The highly restricted Tysabri risk management program tipped the risk-benefit scale in Biogen Idec/Elan’s favor.
Tysabri To Be Priced 20% Higher Than When Initially Launched
Biogen CFO predicts favorable reimbursement for natalizumab, minimizing cost for most patients.